QQ客服 官方微博 反馈留言

浏览/检索结果: 共5条，第1-5条 帮助 限定条件 内容类型：会议论文    专题：复旦大学上海医学院    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 The Efficacy, Safety, and Tolerability of Additional Serelaxin Administration to Standard Therapy in Asian Patients with Acute Heart Failure: The RELAX-AHF-ASIA trial 会议论文 作者:  Sato, Naoki;  Lam, Carolyn S. P.;  Teer-Link, John R.;  Greenberg, Barry H.;  Tsutsui, Hiroyuki 收藏  |  浏览/下载：9/0  |  提交时间：2019/12/05 Phase II clinical trial of metronomic oral capecitabine therapy combined with aromatase inhibitors in postmenopausal metastatic and recurrent breast cancer resistant to first-line aromatase inhibitors 会议论文 作者:  Jian-wei, L.;  Xiao-qing, J.;  Li, L.;  Yu-jie, W.;  Zhi-min, S. 收藏  |  浏览/下载：6/0  |  提交时间：2019/12/19 Comparison of Converting Therapy between Ibutilide and Propafenone in Chinese Patients with Atrial Fibrillation and Atrial Flutter 会议论文 作者:  Wu, Y.;  Jian, W.;  Yan, X. W.;  Hu, D. Y.;  Liu, X. H. 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/19 Can one drug fit all? - urban Chinese population has high prevalence of CAD and stroke with unique pattern of risk factors - a study of CCMR 会议论文 作者:  Hu, D. Y.;  Yu, J. M.;  Sun, Y. H.;  Jian, F.;  Liu, H. 收藏  |  浏览/下载：1/0  |  提交时间：2019/12/19 Efficacy and safety of erlotinib as first-line maintenance in NSCLC following non-progression with chemotherapy: results from the phase III SATURN study 会议论文 作者:  Cappuzzo, Federico;  Coudert, Bruno;  Wierzbicki, Rafal;  Wu Yi-Long;  Gonzalez, Emilio E. 收藏  |  浏览/下载：2/0  |  提交时间：2019/12/19